Trial · NCT01664949
Adverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 28
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Eye irritation | Eye disorders | Carboxymethylcellulose Based Eye Drop Formulation A | 15 | 224 | |
| other | Eye irritation | Eye disorders | OPTIVE™ | 6 | 236 | |
| serious | Atrial fibrillation | Cardiac disorders | Carboxymethylcellulose Based Eye Drop Formulation A | 1 | 224 | |
| serious | Atrial fibrillation | Cardiac disorders | OPTIVE™ | 0 | 236 | |
| serious | Pyelonephritis acute | Infections and infestations | Carboxymethylcellulose Based Eye Drop Formulation A | 1 | 224 | |
| serious | Pyelonephritis acute | Infections and infestations | OPTIVE™ | 0 | 236 | |
| serious | Cardiac failure | Cardiac disorders | Carboxymethylcellulose Based Eye Drop Formulation A | 1 | 224 | |
| serious | Cardiac failure | Cardiac disorders | OPTIVE™ | 0 | 236 | |
| serious | Myocardial infarction | Cardiac disorders | Carboxymethylcellulose Based Eye Drop Formulation A | 1 | 224 | |
| serious | Myocardial infarction | Cardiac disorders | OPTIVE™ | 0 | 236 | |
| serious | Anxiety disorder | Psychiatric disorders | Carboxymethylcellulose Based Eye Drop Formulation A | 1 | 224 | |
| serious | Anxiety disorder | Psychiatric disorders | OPTIVE™ | 0 | 236 | |
| serious | Carotid artery stenosis | Nervous system disorders | Carboxymethylcellulose Based Eye Drop Formulation A | 1 | 224 | |
| serious | Carotid artery stenosis | Nervous system disorders | OPTIVE™ | 0 | 236 | |
| serious | Arthralgia | Musculoskeletal and connective tissue disorders | Carboxymethylcellulose Based Eye Drop Formulation A | 1 | 224 | |
| serious | Arthralgia | Musculoskeletal and connective tissue disorders | OPTIVE™ | 0 | 236 | |
| serious | Benign prostatic hyperplasia | Reproductive system and breast disorders | Carboxymethylcellulose Based Eye Drop Formulation A | 0 | 224 | |
| serious | Benign prostatic hyperplasia | Reproductive system and breast disorders | OPTIVE™ | 1 | 47 | |
| serious | Appendicitis | Infections and infestations | Carboxymethylcellulose Based Eye Drop Formulation A | 0 | 224 | |
| serious | Appendicitis | Infections and infestations | OPTIVE™ | 1 | 236 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01664949/events